首页> 美国卫生研究院文献>Stem Cells Translational Medicine >Concise Review: Guidance in Developing Commercializable Autologous/Patient-Specific Cell Therapy Manufacturing
【2h】

Concise Review: Guidance in Developing Commercializable Autologous/Patient-Specific Cell Therapy Manufacturing

机译:简要评论:开发可商业化的自体/患者特异性细胞疗法制造的指南

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cell therapy is poised to play an enormous role in regenerative medicine. However, little guidance is being made available to academic and industrial entities in the start-up phase. In this technical review, members of the International Society for Cell Therapy provide guidance in developing commercializable autologous and patient-specific manufacturing strategies from the perspective of process development. Special emphasis is placed on providing guidance to small academic or biotech researchers as to what simple questions can be addressed or answered at the bench in order to make their cell therapy products more feasible for commercial-scale production. We discuss the processes that are required for scale-out at the manufacturing level, and how many questions can be addressed at the bench level. The goal of this review is to provide guidance in the form of topics that can be addressed early in the process of development to better the chances of the product being successful for future commercialization.
机译:细胞疗法有望在再生医学中发挥巨大作用。但是,在启动阶段,几乎没有提供给学术和工业实体的指导。在本技术综述中,国际细胞疗法学会的成员从过程开发的角度为开发可商业化的自体和针对患者的制造策略提供了指导。特别强调的是为小型学术或生物技术研究人员提供指导,以指导他们在板凳上可以解决或回答哪些简单的问题,以使其细胞疗法产品更适合商业规模生产。我们讨论了在制造级别进行横向扩展所需的过程,以及在基准级别可以解决多少个问题。这篇综述的目的是提供主题形式的指导,这些主题可以在开发过程的早期进行解决,以提高产品成功用于未来商业化的机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号